期刊
PEDIATRIC ALLERGY AND IMMUNOLOGY
卷 27, 期 3, 页码 236-241出版社
WILEY
DOI: 10.1111/pai.12524
关键词
allergy; allergic diseases; allergen immunotherapy; atopic; prevention; sensitization
资金
- Nestle
- ALK-Abello
- Allergy Therapeutics
- Circassia
- LETI
- Merck USA
- Allergopharma
- Bencard
- HAL
- Lovafarma
- Novartis
- Stallergenes
- Biotech Tools
- Lofarma
- Symbiopharm
- Stallergens
- GSK
- MERCK
- ABBVIE
- Menarini
- Meda
- Uriach
- Sanofi
- Menarini Meda
- ALK Abello
- HAL Allergy
- Artu Biologicals
- Allergy Therapeutics/Bencard
- Hartington
- Novartis/Leti
- GlaxoSmithKline
- Essex Pharma
- Cytos
- Curalogic
- Roxall
- Biomay
- Thermo Fisher
- European Union
- Biotech Tools s.a.
- Meda Pharma GmbH
- Stalleergenes
- Thermo-Fisher
- Asthma UK [MRC-Asthma UK Centre] Funding Source: researchfish
- Medical Research Council [G1000758, G0902018, MR/M008517/1] Funding Source: researchfish
- MRC [MR/M008517/1, G0902018] Funding Source: UKRI
BackgroundThe European Academy of Allergy and Clinical Immunology (EAACI) is in the process of developing the EAACI Guidelines for Allergen Immunotherapy (AIT) for the Prevention of Allergic Disease. We seek to critically assess the effectiveness, cost-effectiveness, and safety of AIT in the prevention of allergic disease. MethodsWe will undertake a systematic review, which will involve searching international biomedical databases for published, in progress and unpublished evidence. Studies will be independently screened against pre-defined eligibility criteria and critically appraised using established instruments. Data will be descriptively and, if possible and appropriate, quantitatively synthesized. DiscussionThe findings from this review will be used to inform the development of recommendations for EAACI's Guidelines on AIT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据